Comparison of the Antiviral Activity of Remdesivir, Chloroquine, and Interferon-β as Single or Dual Agents Against the Human Beta-Coronavirus OC43
Brady T. Hickerson(United States Food and Drug Administration), Natalia A. Ilyushina(United States Food and Drug Administration)
Cited by 5
Related Papers
Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections
|Nature Communications|2022|13